Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preference of Tegaserod vs PEG 3350 in Constipation
NCT00171522Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegaserod in constipation (2 arms), sponsored by Novartis. Primary endpoint: Patient preference for tegaserod compared to PEG 3350 at 35 days. Started May 2005; status: completed.
02
Drugs
tegaserod
03
Conditions
constipation
Beyond the preview
Go deeper on NCT00171522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171522.